ESRRA
Basic information
Region (hg38): 11:64305497-64316743
Previous symbols: [ "ESRL1" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ESRRA gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 3 | |||||
missense | 23 | 24 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 23 | 2 | 2 |
Variants in ESRRA
This is a list of pathogenic ClinVar variants found in the ESRRA region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-64307201-A-C | not specified | Uncertain significance (Jun 16, 2024) | ||
11-64307229-C-T | not specified | Uncertain significance (Mar 15, 2024) | ||
11-64307252-G-A | not specified | Uncertain significance (Feb 16, 2023) | ||
11-64307259-C-T | not specified | Uncertain significance (Jan 22, 2024) | ||
11-64307260-G-A | Likely benign (Apr 26, 2018) | |||
11-64307271-C-T | Benign (Dec 31, 2019) | |||
11-64307277-C-T | not specified | Uncertain significance (Nov 01, 2022) | ||
11-64307291-G-A | not specified | Uncertain significance (Apr 28, 2023) | ||
11-64307350-G-C | not specified | Uncertain significance (Oct 25, 2022) | ||
11-64307369-C-A | not specified | Uncertain significance (Jun 30, 2023) | ||
11-64307372-G-C | not specified | Uncertain significance (Dec 17, 2023) | ||
11-64307375-G-A | not specified | Uncertain significance (Apr 13, 2022) | ||
11-64307437-C-T | Likely benign (Nov 08, 2018) | |||
11-64314039-G-C | not specified | Uncertain significance (Nov 14, 2023) | ||
11-64314256-G-A | not specified | Uncertain significance (Feb 26, 2024) | ||
11-64314317-G-A | not specified | Uncertain significance (Dec 20, 2023) | ||
11-64314326-C-G | not specified | Uncertain significance (Dec 19, 2022) | ||
11-64314338-T-C | not specified | Uncertain significance (Sep 01, 2021) | ||
11-64314346-G-A | not specified | Uncertain significance (Nov 08, 2022) | ||
11-64314842-G-A | not specified | Uncertain significance (Mar 11, 2024) | ||
11-64314846-C-G | not specified | Uncertain significance (Mar 07, 2023) | ||
11-64315119-T-C | Benign (Dec 18, 2018) | |||
11-64315121-A-T | not specified | Uncertain significance (Jul 20, 2021) | ||
11-64315157-C-G | not specified | Uncertain significance (Apr 04, 2023) | ||
11-64315217-G-A | not specified | Uncertain significance (May 21, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ESRRA | protein_coding | protein_coding | ENST00000405666 | 6 | 11172 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.597 | 0.403 | 124766 | 0 | 6 | 124772 | 0.0000240 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.08 | 161 | 254 | 0.634 | 0.0000162 | 2616 |
Missense in Polyphen | 26 | 89.12 | 0.29174 | 978 | ||
Synonymous | 0.328 | 110 | 114 | 0.961 | 0.00000709 | 954 |
Loss of Function | 2.99 | 3 | 15.8 | 0.189 | 9.23e-7 | 183 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000204 | 0.000194 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000947 | 0.00000883 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000677 | 0.0000654 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'. Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces the expression of PERM1 in the skeletal muscle. {ECO:0000269|PubMed:12522104, ECO:0000269|PubMed:16150865, ECO:0000269|PubMed:17676930, ECO:0000269|PubMed:18063693, ECO:0000269|PubMed:23836911, ECO:0000269|PubMed:9271417}.;
- Pathway
- NHR;Energy Metabolism;Nuclear Receptors;Mitochondrial biogenesis;Preimplantation Embryo;Mitochondrial Gene Expression;Transcriptional regulation by RUNX2;Gene expression (Transcription);regulation of pgc-1a;Generic Transcription Pathway;Nuclear Receptor transcription pathway;RNA Polymerase II Transcription;Regulation of RUNX2 expression and activity
(Consensus)
Recessive Scores
- pRec
- 0.373
Intolerance Scores
- loftool
- rvis_EVS
- -0.36
- rvis_percentile_EVS
- 28.93
Haploinsufficiency Scores
- pHI
- 0.520
- hipred
- Y
- hipred_score
- 0.785
- ghis
- 0.625
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 1.00
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Esrra
- Phenotype
- growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); cellular phenotype; homeostasis/metabolism phenotype; normal phenotype; hematopoietic system phenotype; immune system phenotype; skeleton phenotype;
Zebrafish Information Network
- Gene name
- esrra
- Affected structure
- pharyngeal arch 3-7
- Phenotype tag
- abnormal
- Phenotype quality
- decreased process quality
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;regulation of transcription, DNA-templated;transcription initiation from RNA polymerase II promoter;mitochondrion organization;intracellular receptor signaling pathway;response to estradiol;regulation of cell population proliferation;steroid hormone mediated signaling pathway;regulation of osteoblast differentiation;regulation of osteoclast differentiation;positive regulation of transcription by RNA polymerase II;cartilage development;positive regulation of cellular response to insulin stimulus
- Cellular component
- fibrillar center;nucleus;nucleoplasm;cytoplasm;microtubule cytoskeleton;intercellular bridge
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA binding;DNA-binding transcription factor activity;steroid hormone receptor activity;nuclear receptor activity;steroid binding;protein binding;zinc ion binding;protein domain specific binding;sequence-specific DNA binding